Rituximab
Contents
Description
Rituximab is a chimeric monoclonal antibody targeting CD20-positive B cells, approved for various hematologic malignancies and autoimmune conditions. It has been used off-label in steroid-resistant nephrotic syndrome type 1 (congenital nephrotic syndrome) and shows promise in certain cases of treatment-resistant disease. The drug depletes B lymphocytes, reducing antibody-mediated kidney damage.
Indications & Therapeutic Use
non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, steroid-resistant nephrotic syndrome
Linked Diseases:
Global Availability (11 countries)
Buy / Source Rituximab — GNH India
70 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | rituximab |
| Brands | 1 brand available |
| Active Ingredient | rituximab |
| Drug Class | non-Hodgkin lymphoma |
| Manufacturer | Genentech/Roche |
| Dosage Forms | IV infusion 10mg/mL (100mg/10mL, 500mg/50mL vials) |
| Medical Code | L01FA01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00498368 |
| Countries | 11 countries |